Kamada (NASDAQ:KMDA) Upgraded by StockNews.com to Buy

StockNews.com upgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a buy rating in a research report sent to investors on Wednesday.

Several other equities research analysts have also recently commented on KMDA. TheStreet raised shares of Kamada from a d+ rating to a c- rating in a research report on Thursday, August 24th. HC Wainwright reaffirmed a buy rating and issued a $11.00 price objective on shares of Kamada in a research report on Thursday, August 17th.

Kamada Stock Up 2.2 %

Shares of KMDA opened at $5.63 on Wednesday. The stock has a market cap of $252.34 million, a price-to-earnings ratio of 70.38 and a beta of 0.97. The company has a quick ratio of 0.75, a current ratio of 1.97 and a debt-to-equity ratio of 0.06. Kamada has a 12 month low of $3.72 and a 12 month high of $5.85. The company has a 50-day moving average price of $5.22 and a two-hundred day moving average price of $4.87.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, August 16th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $37.44 million during the quarter, compared to analyst estimates of $34.18 million. Kamada had a net margin of 2.35% and a return on equity of 7.42%. During the same quarter last year, the business posted $0.07 earnings per share. Equities analysts predict that Kamada will post 0.06 EPS for the current fiscal year.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently made changes to their positions in KMDA. State of Tennessee Treasury Department bought a new stake in shares of Kamada during the 2nd quarter worth approximately $38,000. Group One Trading L.P. lifted its holdings in shares of Kamada by 103.7% during the 1st quarter. Group One Trading L.P. now owns 11,064 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 307,831 shares during the period. Bank of Montreal Can bought a new stake in shares of Kamada during the 2nd quarter worth approximately $70,000. JPMorgan Chase & Co. bought a new stake in shares of Kamada during the 2nd quarter worth approximately $83,000. Finally, Metis Global Partners LLC lifted its holdings in shares of Kamada by 19.2% during the 4th quarter. Metis Global Partners LLC now owns 33,001 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 5,323 shares during the period. Institutional investors own 34.08% of the company’s stock.

Kamada Company Profile

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD.